A comparison of the platinum analogues in bladder cancer cell lines

Urologia Internationalis

Volumn 79, Issue 1, 2007, Pages 67-72

  Powles, Thomas ^a,b   Perry, Jacky ^a   Shamash, Jonathan ^a   Liu, Wai ^a   Oliver, Tim ^a   Joel, Simon ^a  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^b Hurlingham Mansions   (United Kingdom)

Author keywords

Bladder cancer; Cell lines; Oxaliplatin

Indexed keywords

CARBOPLATIN; CISPLATIN; OXALIPLATIN; PLATINUM DERIVATIVE;

ANALYTIC METHOD; APOPTOSIS; ARTICLE; BLADDER CANCER; CANCER CELL; CELL COUNT; CELL CYCLE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL DEATH; CELL VIABILITY; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFICACY; DRUG EXPOSURE; DRUG POTENCY; HUMAN; HUMAN CELL; IC 50; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; CARBOPLATIN; CELL LINE, TUMOR; CISPLATIN; HUMANS; ORGANOPLATINUM COMPOUNDS; URINARY BLADDER NEOPLASMS;

EID: 34447329857     PISSN: 00421138     EISSN: None     Source Type: Journal    
DOI: 10.1159/000102917     Document Type: Article

References (17)

1. von der Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, Moore MJ, Bodrogi I, Albers P, Knuth A, Lippert CM, Kerbrat P, Sanchez Rovira P, Wersall P, Cleall SP, Roychowdhury DF, Tomlin I, Visseren-Grul CM, Conte PF: Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000;18:3068-3077.
2. Loehrer PJ Sr, Einhorn LH, Elson PJ, Crawford ED, Kuebler P, Tannock I, Raghavan D, Stuart-Harris R, Sarosdy MF, Lowe BA: A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 1992;10:1066-1073.
3. Niell HB, Herrod HG, Blatnik AF, Soloway MS: In vitro and in vivo activity of two second generation platinum analogs in murine bladder cancer. J Urol 1985;134:399-402.
4. Lokich J, Anderson N: Carboplatin versus cisplatin in solid tumors: an analysis of the literature. Ann Oncol 1998;9:13-21.
5. Olivares J, Hyman W, Senzer N: A phase II trial of gemcitabine and carboplatin (GC) in patients with transitional cell carcinoma of the urinary tract (TCC). ASCO 2004, abstract 4590.
6. Carles J, Nogue M: Gemcitabine/carboplatin in advanced urothelial cancer. Semin Oncol 2001;28(suppl 10):19-24.
7. Raymond E, Chaney SG, Taamma A, Cvitkovic E: Oxaliplatin: a review of preclinical and clinical studies. Ann Oncol 1998;9:1053-1071.
8. Pendyala L, Creaven PJ: In vitro cytotoxicity, protein binding, red blood cell partitioning, and biotransformation of oxaliplatin. Cancer Res 1993;53:5970-5976.
9. Nehme A, Baskaran R, Nebel S, Fink D, Howell SB, Wang JY, Christen RD: Induction of JNK and c-Abl signalling by cisplatin and oxaliplatin in mismatch repair-proficient and -deficient cells. Br J Cancer 1999;79:1104-1110.
10. Font A, Esteban E, Carles J, Climent M, Gonzalez-Larriba J, Berrocal A: A multicenter phase II trial in unfit patients with locally advanced or metastatic urothelial cancer. ASCO 2004, abstract 4544.
11. Liu WM, Stimson LA, Joel SP: The in vitro activity of the tyrosine kinase inhibitor STI571 in BCR-ABL positive chronic myeloid leukaemia cells: synergistic interactions with anti-leukaemic agents. Br J Cancer 2002;86:1472-1478.
12. Culy CR, Clemett D, Wiseman LR. Oxaliplatin: a review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies. Drugs 2000;60:895-924.
13. Lorusso PM: Oxaliplatin in tumors other than colorectal cancer. Oncology (Williston Park) 2000;14(suppl 11):33-37.
14. Scheeff ED, Briggs JM, Howell SB: Molecular modeling of the intrastrand guanine-guanine DNA adducts produced by cisplatin and oxaliplatin. Mol Pharmacol 1999;56:633-643.
15. Woynarowski JM, Faivre S, Herzig MC, Arnett B, Chapman WG, Trevino AV, Raymond E, Chaney SG, Vaisman A, Varchenko M, Juniewicz PE: Oxaliplatin-induced damage of cellular DNA. Mol Pharmacol 2000;58:920-927.
16. Fink D, Nebel S, Aebi S, Zheng H, Cenni B, Nehme A, Christen RD, Howell SB: The role of DNA mismatch repair in platinum drug resistance. Cancer Res 1996;56:4881-4886.
17. Bonnal C, Ravery V, Toublanc M, Bertrand G, Boccon-Gibod L, Henin D, Grandchamp B: Absence of microsatellite instability in transitional cell carcinoma of the bladder. Urology 2000;55:287-291.